The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
Ken Ohara(Jichi Medical University), Daisuke Nagata(Jichi Medical University), Akito Maeshima(Social Insurance Saitama Chuo Hospital), Maki Asakura(Jichi Medical University), Yasuharu Miyazawa(Sapporo Minami Hospital), Mari Okada(Seoul National University Children's Hospital), Takahiro Masuda(Jichi Medical University), Osamu Saitô(Institute for Global Environmental Strategies), Tetsu Akimoto(Jichi Medical University), Masato Morinari(Stony Brook School), Saki Nakagawa(Okayama University), Kentaro Oka(Jichi Medical University), Takuya Murakami(Jichi Medical University), Atsushi Miki(Jichi Medical University)
Cited by 66
Related Papers
Morning Surge in Blood Pressure as a Predictor of Silent and Clinical Cerebrovascular Disease in Elderly Hypertensives
|Circulation|2003|1.2k
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
|American Journal of Physiology-Renal Physiology|2013|481
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
|American Journal of Physiology-Renal Physiology|2013|308
Periadventitial Adipose Tissue Plays a Critical Role in Vascular Remodeling
|Circulation Research|2009|211
Annual dialysis data report for 2018, JSDT Renal Data Registry: survey methods, facility data, incidence, prevalence, and mortality
|Renal Replacement Therapy|2020|170